EICHORPublic-registry site landscape for NCT03637803, “Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors”, a Oncology study sponsored by 4D pharma plc. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03637803 (registry record) |
| Study title | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors |
| Official title | A Phase I/II Open Label, Safety And Preliminary Efficacy Study of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1/PD-L1 Inhibitors |
| Sponsor | 4D pharma plc |
| Condition(s) | Oncology; Solid Tumor; Non Small Cell Lung Cancer; Renal Cell Carcinoma |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 5 |
| Intervention(s) | MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA] |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03637803.
Eichor generates a preliminary site-risk snapshot for NCT03637803 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
